SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and ...
In 2026, audiences will increasingly prefer sessions that offer a tangible takeaway: a framework, a workflow or a practical ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果